Aqualis ASA is a Norwegian public company focusing on
building a profitable and successful business based on its key
competences within the marine and offshore and healthcare sectors.
The shares of Aqualis have been listed on Oslo BÝrs since 2006 (OSE:
Aqualis ASA, called Clavis Pharma ASA prior to October 2013, was
founded in 2001 when it acquired all the rights to new medicinal
products based on the so-called Lipid Vector Technology (LVT) from
Norsk Hydro. Aqualis developed several drug candidates based on LVT,
and succeeded in bringing two oncology products all the way through
final clinical testing (elacytarabine, in patients with Acute Myeloid
Leukaemia, and CP-4126, in patients with pancreatic cancer).
Unfortunately, none of the products proved more efficacious than
existing therapy in the disease areas tested, and registration and
commercialisation of these products was not initiated. The company
still has a large portfolio of patents and patent application for a
number of drug compounds, as well as license agreements. In November
2013, the company changed its strategic direction to also include a new
major business area of specialised offshore marine and engineering
consultancy services to the oil and gas industry, through the
acquisition of Aqualis Offshore Ltd.